Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

08-02-2024(Thu) 07-02-2024(Wed) 06-02-2024(Tue) 05-02-2024(Mon) 02-02-2024(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
4 Nov, 2019 (Monday)

            
3SBIO(1530)
Analysis¡G
3SBIO (1530) is primarily engaged in the development, manufacture and sale of biopharmaceutical products. The Group recently announced that the Shanghai Stock Exchange formally accepted the spin-off application by Sunshine Guojian, an indirect non-wholly owned subsidiary of the Company, for listing on the STAR Market. The Proposed Spin-off will (i) marketize the price of the equity interests of Sunshine Guojian; (ii) provide new sources of capital for Sunshine Guojian; (iii) enhance corporate and brand awareness on both the Group level and the Spun-off Group level; (iv) increase corporate governance; (v) attract talents to join Sunshine Guojian and enhance the standard, capacity and expertise of Sunshine Guojian; and (vi) enable Sunshine Guojian and the Group to be more focused in developing and strategically planning their respective businesses. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $14.60, Target Price: $16.40, Cut Loss Price: $13.50


CMS(867)
Analysis¡G
For the six months ended June 30, 2019, the company recorded operating income of RMB 2.964 billion, an increase of 11.7% YoY; if excluding the effect of the ¡§two-invoice system¡¨ revenue was RMB 3.402 billion, an increase of 14.4% YoY, mainly because of an increase in sales volume. The profit for the period was RMB 1.168 billion, a YoY increase of 22.2%, mainly due to the continuous growth in turnover and an increase in other gains. The company mainly invests in innovative products of different innovation levels and development stages by making equity investment in overseas R&D companies or achieving strategic collaboration with them. As of June 30, 2019, the company acquired four innovative products with sufficient competitive advantages to meet the clinical needs in Chinese market. The company divides its existing products into cardio-cerebrovascular line, digestion line, ophthalmology line and dermatology line. For1H2019, the company's promotion network covers more than 57,000 hospitals and medical institutions across the country, covering all provincial administrative regions and most prefecture-level administrative regions, and also China's tertiary hospitals, secondary hospitals and the main departments of the tertiary hospital.
Strategy¡G
Buy-in Price: $10.40, Target Price: $11.34, Cut Loss Price: $10.00



GWM (2333.HK) - Good Momentum is Expected to Continue in Q4

Investment Summary

Q3 Profits Increased by near 90% QoQ Significantly

Great Wall Motors recorded the revenue of RMB21.2 billion in Q3, up 18% yoy and 13% qoq. The net profit attributable to stockholders reached RMB1.4 billion, up 507% yoy and 88% qoq. The accumulated revenue in the first three quarters reached RMB62.58 billion, down 6.1% yoy, a sharp decrease from -15% in the semi-annual report. The net profit attributable to stockholders reached RMB2,917 million, down 25.7% yoy, down 59% in the semi-annual report.

ASP Rebounded and Sales Volume Increase Pushed Profitability to Rebound Rapidly

Great Wall Motors was at the forefront of the industry in terms of ASP. Benefiting from the reduction of discounts after the switch of the China V/VI vehicle emission standards and the increase in the proportion of F-series with high selling prices, the average price of single vehicles of the Company in the first three quarters of 2019 was approximately RMB79,700, RMB89,400 and RMB91,900, respectively, showing a trend of increasing quarter by quarter. However, Great Wall Motors sharply reduced its inventory in the same period of last year, and the average price of single vehicles in the first three quarters of last year was RMB103,500, RMB102,000 and RMB87,600, respectively.

In terms of sales volume, the Company recorded sales volume of 230,000 vehicles in Q3, up 12.4% yoy, far better than the industry average decline of 5.5%, and the market share expanded by 0.61 ppts against the trend. In the first three quarters, a total of 724,000 vehicles were sold, up 7% yoy, reaching 68% of the annual objective of 1.07 million vehicles, with a good grasp of the annual objective.

The good performance of increase in sales volume and price pushed the gross margin in Q3 to rebound sharply to 18.49% from 13.65% in the same period last year, a sharp increase of 4.93 ppts qoq and 4.84 ppts yoy, compared with the gross margin of 13.72% in Q1 and 13.56% in Q2.

In terms of expenses: In Q3, the sales expense rate decreased by 1.25 ppts yoy and increased by 1.9 ppts qoq. Administration expense rate was basically the same yoy with a slight decrease of 0.2 ppts qoq. The R&D expense rate increased by 1.8 ppts yoy, which was basically the same qoq. The Company continued to promote the R&D investment in new products, new technologies and new platforms. The new platforms will simultaneously support fuel, PHEV and EV power modes. The hydrogen energy technology centre had also been built.

Good Momentum is Expected to Continue in Q4

Sales of passenger vehicle industry in China continued to improve in October. Considering the gradual dissipation of the overdraft effect of the switch to China VI vehicle emission standards and the low inventory, and combined with high season effect and low base factor, it is expected that the retail sales in the industry in Q4 will become positive yoy. As the leader of SUV industry, the overall performance of the Company was better than that of the industry, and the sales volume is expected to continue to increase in the future as the industry recovers. After the new platform is put into production in 2020, it will make up for the shortcomings of the Company's products in lightweight and provide a richer engine power allocation system. The two new SUV models built on this platform will be expected to come into market next year. A brand new electric vehicle will also be launched in terms of new energy brand Euler. The first hydrogen fuel cell vehicle is expected to be officially launched in 2022.

It is worth mentioning that the overseas business of the Company is gradually improving. In the first three quarters, exports increased by 41% to 50,000 vehicles yoy. The monthly sales volume of Russian factories had exceeded 1,000 vehicles. In the future, the Company will radiate to the Eastern European market and prepare for its entry into the international market again.

Investment Thesis

In terms of valuation, we adjust our target price to HK$6.5, equivalent to 11.5/10.4 P/E and 1.0/0.9 P/B ratio in 2019/2020. We give the rating of ¡§Hold¡¨. (Closing price as at 31 October)

Risk

New vehicle sales fall short of expectations

The SUV market dramatically worsens

The progress of new energy vehicle project is poorer than expectations

Financials

Click Here for PDF format...




Recommendation on 4-11-2019
RecommendationHold
Price on Recommendation Date$ 6.380
Suggested purchase priceN/A
Target Price$ 6.500
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]